Literature DB >> 9169497

Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.

T Ebara1, R Ramakrishnan, G Steiner, N S Shachter.   

Abstract

The mechanism of apolipoprotein (apo) CIII-induced hypertriglyceridemia remains uncertain. We crossed apoCIII transgenic and apoE gene knockout (apoE0) mice, and observed severe hypertriglyceridemia with plasma triglyceride levels of 4,521+/-6, 394 mg/dl vs. 423+/-106 mg/dl in apoE0 mice, P < 0.00001 for log(triglycerides [TG]). Cholesterols were 1,181+/-487 mg/dl vs. 658+/-151 mg/dl, P < 0.0001. Lipoprotein fractionation showed a marked increase in triglyceride-enriched chylomicrons+VLDL. This increase was limited to the lowest density (chylomicrons and Sf 100-400) subfractions. Intermediate density lipoproteins (IDL)+LDL increased moderately, and HDL decreased. There was no significant increase in triglyceride production in apoCIII transgenic/apoE0 mice. The clearance of VLDL triglycerides, however, was significantly decreased. Lipoprotein lipase in postheparin plasma was elevated, but activation studies suggested LPL inhibition by both apoCIII transgenic and apoCIII transgenic/apoE0 plasma. ApoCIII overexpression also produced a marked decrease in VLDL glycosaminoglycan binding which was independent of apoE. The predominant mechanism of apoCIII-induced hypertriglyceridemia appears to be decreased lipolysis at the cell surface. The altered lipoprotein profile that was produced also allowed us to address the question of the direct atherogenicity of chylomicrons and large VLDL. Quantitative arteriosclerosis studies showed identical results in both apoCIII transgenic/apoE0 and apoE0 mice, supporting the view that very large triglyceride-enriched particles are not directly atherogenic.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9169497      PMCID: PMC508113          DOI: 10.1172/JCI119456

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

1.  Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl.

Authors:  N S Shachter; T Ebara; R Ramakrishnan; G Steiner; J L Breslow; H N Ginsberg; J D Smith
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoproteins lipase from different sources.

Authors:  R J Havel; C J Fielding; T Olivecrona; V G Shore; P E Fielding; T Egelrud
Journal:  Biochemistry       Date:  1973-04-24       Impact factor: 3.162

3.  Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein.

Authors:  W V Brown; M L Baginsky
Journal:  Biochem Biophys Res Commun       Date:  1972-01-31       Impact factor: 3.575

4.  Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apoproteins.

Authors:  E Windler; Y Chao; R J Havel
Journal:  J Biol Chem       Date:  1980-09-10       Impact factor: 5.157

5.  The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat.

Authors:  S H Quarfordt; G Michalopoulos; B Schirmer
Journal:  J Biol Chem       Date:  1982-12-25       Impact factor: 5.157

6.  Studies of the proteins in human plasma very low density lipoproteins.

Authors:  W V Brown; R I Levy; D S Fredrickson
Journal:  J Biol Chem       Date:  1969-10-25       Impact factor: 5.157

7.  Changing relative proportions of apolipoproteins CII and CIII of very low density lipoproteins in hypertriglyceridaemia.

Authors:  L A Carlson; D Ballantyne
Journal:  Atherosclerosis       Date:  1976 May-Jun       Impact factor: 5.162

8.  The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E.

Authors:  E E Windler; P T Kovanen; Y S Chao; M S Brown; R J Havel; J L Goldstein
Journal:  J Biol Chem       Date:  1980-11-10       Impact factor: 5.157

9.  Characterization of human very low density lipoproteins containing two electrophoretic populations: double pre-beta lipoproteinemia and primary dysbetalipoproteinemia.

Authors:  A Pagnan; R J Havel; J P Kane; L Kotite
Journal:  J Lipid Res       Date:  1977-09       Impact factor: 5.922

10.  Differential characteristics of purified hepatic triglyceride lipase and lipoprotein lipase from human postheparin plasma.

Authors:  M L Baginsky; W V Brown
Journal:  J Lipid Res       Date:  1977-07       Impact factor: 5.922

View more
  41 in total

Review 1.  Postprandial lipemia and coronary risk.

Authors:  W Patsch; H Esterbauer; B Föger; J R Patsch
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

Review 2.  The genetics of familial combined hyperlipidaemia.

Authors:  Martijn C G J Brouwers; Marleen M J van Greevenbroek; Coen D A Stehouwer; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Nat Rev Endocrinol       Date:  2012-02-14       Impact factor: 43.330

3.  Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets.

Authors:  Mikael Larsson; Evelina Vorrsjö; Philippa Talmud; Aivar Lookene; Gunilla Olivecrona
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

4.  Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.

Authors:  Arman Qamar; Sumeet A Khetarpal; Amit V Khera; Atif Qasim; Daniel J Rader; Muredach P Reilly
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-06-11       Impact factor: 8.311

5.  ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.

Authors:  Philip L S M Gordts; Ryan Nock; Ni-Huiping Son; Bastian Ramms; Irene Lew; Jon C Gonzales; Bryan E Thacker; Debapriya Basu; Richard G Lee; Adam E Mullick; Mark J Graham; Ira J Goldberg; Rosanne M Crooke; Joseph L Witztum; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2016-07-11       Impact factor: 14.808

6.  Hypertriglyceridemia and delayed clearance of fat load in transgenic rabbits expressing human apolipoprotein CIII.

Authors:  Yinyuan Ding; Yuhui Wang; Hong Zhu; Jianglin Fan; Liqing Yu; George Liu; Enqi Liu
Journal:  Transgenic Res       Date:  2010-12-01       Impact factor: 2.788

7.  Alterations in hepatic metabolism in fld mice reveal a role for lipin 1 in regulating VLDL-triacylglyceride secretion.

Authors:  Zhouji Chen; Matthew C Gropler; Jin Norris; John C Lawrence; Thurl E Harris; Brian N Finck
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-31       Impact factor: 8.311

8.  Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits.

Authors:  Haizhao Yan; Manabu Niimi; Fumikazu Matsuhisa; Huanjin Zhou; Shuji Kitajima; Yajie Chen; Chuan Wang; Xiawen Yang; Jian Yao; Dongshan Yang; Jifeng Zhang; Masami Murakami; Katsuyuki Nakajima; Yao Wang; Enqi Liu; Jingyan Liang; Y Eugene Chen; Jianglin Fan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-08-06       Impact factor: 8.311

9.  Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver.

Authors:  Eliete J B Bighetti; Patrícia R Patrício; Andrea C Casquero; Jairo A Berti; Helena C F Oliveira
Journal:  Lipids Health Dis       Date:  2009-11-23       Impact factor: 3.876

10.  ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.

Authors:  Anne Hiukka; Marcus Ståhlman; Camilla Pettersson; Malin Levin; Martin Adiels; Susanne Teneberg; Eeva S Leinonen; Lillemor Mattsson Hultén; Olov Wiklund; Matej Oresic; Sven-Olof Olofsson; Marja-Riitta Taskinen; Kim Ekroos; Jan Borén
Journal:  Diabetes       Date:  2009-06-05       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.